Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golimumab/Guselkumab - Janssen Research & Development

Next Previous
Drug Profile

Golimumab/Guselkumab - Janssen Research & Development

Alternative Names: JNJ-4804; JNJ-4804 combination therapy; JNJ-78934804

Latest Information Update: 27 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 21 Feb 2023 Phase-II clinical trials in Crohn's disease (In adults, In the elderly) in Bulgaria, Portugal, Norway, Slovenia, Sweden, Denmark, Greece (SC) (NCT05242471) (EudraCT2021-003314-39)
  • 16 Feb 2023 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Norway, Denmark, Sweden, Portugal, Slovenia (SC) (NCT05242484) (EudraCT2021-005528-39)
  • 13 Feb 2023 Phase-II clinical trials in Psoriatic arthritis in USA (unspecified route) (Johnson & Johnson pipeline, February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top